Zobrazeno 1 - 10
of 370
pro vyhledávání: '"new drug development"'
Autor:
Davide Di Tonno, Laura Martena, Manuela Taurisano, Caterina Perlin, Anna Chiara Loiacono, Stefano Lagravinese, Santo Marsigliante, Michele Maffia, Susanna Esposito, Gianluca Villa, Giovanni Gori, Leonardo Bray, Alessandro Distante, Alessandro Miani, Prisco Piscitelli, Alberto Argentiero
Publikováno v:
Epidemiologia, Vol 5, Iss 1, Pp 137-145 (2024)
Phase I clinical trials represent a critical point in drug development because the investigational medicinal product is being tested in humans for the first time. For this reason, it is essential to evaluate and identify the Maximum Tolerated Dose (M
Externí odkaz:
https://doaj.org/article/9da6f301bfea405781f2a6adfefbe736
Autor:
Keri Toner, Carl E. Allen, Shweta Jain, Brad Kahl, John Leonard, Heather Wasserstrom, Jonathan W. Friedberg, Nita L. Seibel, Kara Kelly
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 921-926 (2023)
Abstract Lymphoma is one of the most common cancers in adolescents and young adults, but historically, this population has had lower clinical trial enrollment and improvements in overall survival as compared to other age populations. There are multip
Externí odkaz:
https://doaj.org/article/288e72642e4543a781aee5d684258469
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-5 (2023)
Abstract The term “metastatic cascade” defines a process whereby few tumor cells complete a sequence of steps to leave the primary tumor to reach one or more sites elsewhere in the body, usually through the bloodstream to develop one or several m
Externí odkaz:
https://doaj.org/article/4d07fb1161ac4bcf89531b6d859386e6
Publikováno v:
SLAS Discovery, Vol 28, Iss 4, Pp 119-137 (2023)
Three-dimensional (3D) cell culture technology has been steadily studied since the 1990′s due to its superior biocompatibility compared to the conventional two-dimensional (2D) cell culture technology, and has recently developed into an organoid cu
Externí odkaz:
https://doaj.org/article/13a46c9952474f78af2a531badb1454f
Autor:
Mahmoudi, Hesam
After numerous renewals and reignitions since the initiation of the "War on Cancer" more than five decades ago, the recent reignition of "Moonshot to Cure Cancer" points to the systemic persistence of cancer as a major cause of loss of life and livel
Externí odkaz:
http://hdl.handle.net/10919/116191
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hua BAI, Shuyang ZHANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 25, Iss 7, Pp 511-516 (2022)
A large number of investigator-initiated clinical trials (IIT) were conducted in China, some of them should play an important supporting role in new drug development. Due to the large number, small scale and uneven quality of IIT in China, especially
Externí odkaz:
https://doaj.org/article/ea0e8f39145e4f1890c06bed7cdcd941
Autor:
Vincent Ribrag, Julio C. Chavez, Carola Boccomini, Jason Kaplan, Jason C. Chandler, Armando Santoro, Paolo Corradini, Ian W. Flinn, Ranjana Advani, Philippe A. Cassier, Randeep Sangha, Vaishalee P. Kenkre, Iris Isufi, Shailaja Uttamsingh, Patrick R. Hagner, Anita K. Gandhi, Frank Shen, Sophie Michelliza, Harald Haeske, Kristen Hege, Michael Pourdehnad, John Kuruvilla
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 139-153 (2022)
Abstract There is a need for additional treatment options for patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) who do not benefit from available therapies. We examined combinations of the cereblon E3 ligase modulator (CELM
Externí odkaz:
https://doaj.org/article/96c484da7911405ebd05aa9e00d581f2